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It is clear that passively administered 7S antibody can inhibit both the IgM and 
IgG responses and that the effect is specific with regard  to antigen (1-3). Although 
there is general agreement on the effect of passively administered 7S antibody, there 
is no such agreement concerning the mechanism of this effect. ():f the several possible 
mechanisms, the first and most obvious is that antibody simply combines with the ma- 
jority of the antigenic determinants and neutralizes their effectiveness. With regard to 
the response to heterologous erythrocytes, it is clear that this mechanism cannot ac- 
count entirely for the inhibition since severe suppression can be obtained at concentra- 
tions of antibody capable of combining with only a  small proportion  (< 1%)  of  the 
available antigenic determinants (4-6). An alternative but closely related possibility 
is that the passively administered antibody causes the destruction or deviation of anti- 
gen before it contacts the cells in the antigen-sensitive  unit. Once again, this mechanism 
does not easily account for the inhibition of humoral responses to heterologous erythro- 
cytes,  since  antibody-mediated inhibition can  occur  under  conditions where  other 
antigen-dependent functions (e.g., antigen competition [7! and priming of thymus-de- 
rived (T) cells  1 [81 are not suppressed. Since direct effects on antigen appear unlikely to 
be the sole mechanism for antibody mediated suppression, it has been suggested that 
antibody may act directly on one of the cells involved in initiation of humoral immune 
responses. 
As shown by many investigations, the antigen-sensitive unit with respect to the re- 
sponse to heterologous erythrocytes is composed of  bone marrow-derived  (B)  and T 
lymphocytes and nonlymphoid accessory (A)  cells. Presumably, alteration o[ the func- 
tion of any of these cells could result in suppression of the humoral response to heterol- 
ogous erythrocytes.  The in vivo experiments of Ryder and  Schwartz  (5)  and the in 
vitro studies of Pierce  (9)  suggested that inhibition takes place at the level of the A 
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cell. The work of Feldmann and Diener (10, 11), using a slightly different in vitro sys- 
tem, suggested that inhibition takes place at the level of the B cell. In addition, Sinclair 
and  Chan  (12)  have presented  evidence that  interaction  of  antigen,  antibody,  and 
lymphoid cells results in inactivation of the lymphoid cells. 
The difficulty in interpreting  the data  referred  to above is that  the evidence 
implicating one or another cell type is indirect. Our approach  to elucidating the 
cellular site of action of antibody has been  to identify the cell type capable  of 
reconstituting  an inhibited  spleen  cell population.  This should  clearly identify 
the cell type which has been functionally inactivated by exposure to antibody. 
Using ti~Jis approach,  we have attempted  to critically analyze a  specific in vitro 
system in order to identify unequivocally the site of action of passively adminis- 
tered  antibody.  In  this system,  it is clear that  antibody  can act by combining 
with the A  cell and inhibiting its normal function. 
Materials and Methods 
Mice.--The mice used were C57BL/6JOci X  C3H/HeOci F1 hybrids  (C3B6F1)  (bred in 
our laboratories), C3H/HeDub (purchased  from Flow Laboratories, Inc., Rockville, Md.) and 
DBA/2J  (purchased from the Jackson Laboratory,  Bar Harbor, Maine). All mice used were 
approximately 2 mo old. 
Antigens.---Sheep  erythrocytes  (SRBC)  and  horse erythrocytes  (HRBC)  (obtained from 
Woodland  Farms,  Guelph,  Ontario,  Canada),  washed  three  times  in  phosphate-buffered 
saline  (PBS) ~,nd diluted to the appropriate concentration in PBS before intravenous injec- 
tion, were used as antigens. 
7S Antibocly Preparations.--7S antibody was prepared from two sources:  serum from hy- 
perimmunized mice and ascitic fluid  from hyperimmunized mice in which an ascites was in- 
duced by injection of Freund's complete adjuvant. The 7S fraction of the serum was isolated 
by  Sephadex  G-200  chromatography.  The  7S fraction of the ascitic fluid  was obtained  by 
saturated  ammonium  sulfate  precipitation  followed by  Sephadex  G-200  chromatography. 
Normal 7S preparations were obtained in the same way, but from unimmunized mice. 
A ssays.-- 
IgM-plaque-forming  cells (PFC):  Splenic IgM-PFC were assayed using the technique of 
Jerne et al.  (13) as modified by Kennedy et al.  (14). 
Protein concentration:  Measurements of protein concentration were carried out according 
to the method of Lowry et al.  (15). 
Hemolytic tiler:  7S antibody preparations were titrated using the microtiter system (Cooke 
Engineering Co., Alexandria, Va.).  Twofold serial dilutions of the antibody were prepared. 
0.025 ml of SRBC at a concentration of 4 X  l0 s SRBC/ml was added to 0.025 ml of diluted 
antibody. After 10 min incubation at 37°C,  0.025  ml of a  mixture of 30% guinea pig serum 
(GPS)  (as a  source  of complement) and 6% rabbit antimouse IgG serum (for augmentation 
of 7S-induced hemolysis) was added. This resulted in a final concentration of 10% GPS and 
2% anti-IgG serum, concentrations which we had previously established as optimal. After 60 
min incubation at 37°C, the titer was read as the reciprocal of the lowest antibody concentra- 
tion providing apparently complete hemolysis. The serum-derived 7S antibody preparations 
had a facilitated hemolytic titer of ~5,000 at 1 mg/ml. The ascites-derived 7S antibody prep- 
arations had a facilitated hemolytic titer of ~20,000 at 1 mg/ml. 
Hemaggh*tination titer:  Hemagglutination titers were carried out as follows.  Serial two- 
fold dilutions (in PBS) of the antibody preparations were prepared to a volume of 0.1 ml in 
small (6 ml) plastic tubes. To each dilution was added 0.1 ml of SRBC at 1 X  108/ml. The 872  MECtlANIS~[  OF  7S  INHIBITION 
tubes were incubated for 20 rain at 37°C and then centrifuged at 150 g for 10 rain. The ag- 
glutination titer was read as the reciprocal of the lowest concentration providing visible he- 
magglutination. 
Culture System.--The method used was the double-chamber technique of Marbrook  (16) 
as modified by Osoba (17).  (The inner chamber volume was 1 ml and outer chamber volume 
was 9  ml.)  The medium used was either 1066 with 20 ~g/ml of L-asparagine added, or ~x 
medium, both supplemented with 10% fetal calf serum. Cultures were assayed for IgM-PFC 
on day 4. In our hands an optimum response was obtained at a cell density of 15-20  X  106 
spleen cells and 1 >(  10 ~ erythrocytes/culture, and these concentrations were used in all ex- 
periments unless otherwise stated. All experimental points represent averages of  the PFC 
measured in three to five cultures. 
Irradiation.--Cells  were irradiated using a  137Cs irradiator at a dose rate of 102 rad/min. 
Mice to be used as recipients for in vivo assays were exposed to 950 rad. 
In Vivo Measurement of the Immune Response.--Cells to be assayed were injected into ir- 
radiated recipients along with antigen (10 s  SRBC/recipient) and spleens were assayed for 
IgM-PFC on day 7. All groups consisted of 8-12 mice. 
Cell Suspensions.--Spleen  cell suspensions were obtained by pressing the tissue through a 
stainless steel screen as described previously (18). Peritoneal exudate cells were obtained by 
flushing the peritoneal cavity of exsanguinated normal mice with 5 ml of PBS. 
Anti-O Treatment of Cells.--Anti-O antibody, prepared by injection of C3H  thymus cells 
into AKR mice, was kindly provided by R. Gorczynski. This antibody has been shown to be 
specifically  toxic for T  cells, having no effect on B  or A cells  (19). Cells were incubated (in 
medium) at a concentration of 1 >(  107 cells/ml in the presence of 20% of the anti-0 prepara- 
tion for 60 mln at 37°C. The cells were then washed and resuspended (to 1 X  107 cells/ml) in 
medium containing 20% GPS (as a source of complement). After 45 rain incubation the cells 
were spun down and washed three times before culturing. 
Sedimentation Analysis.--Velocity  sedimentation cell  separation,  which  separated  cells 
primarily on the basis of size, was performed as described elsewhere (20). A glass sedimentation 
chamber 11.0 cm in diameter was used. A total of 30-40 >(  107 cells were loaded at a concen- 
tration of 107 cells/ml in 0.2% bovine serum albumin (BSA) in PBS. 0.5-2% BSA in PBS- 
buffered step gradient was used (20). Cells were sedimented for 4 h at 4°C. 
Conjugation of 7S with Fluorescein Isothiocyanate (FITC).--FITC conjugation was carried 
out as described by Holborrow and Johnson (21). The conjugation mixture consisted of 10 ml 
of the 7S preparation at a concentration of 1 mg protein/ml in a carbonate-bicarbonate buffer 
at pH 9,  to which was added 2 mg FITC. This was stirred overnight at 4°C  and dialyzed 
against PBS. Conjugation of mouse albumin was carried out similarly. The fluorescein  to pro- 
tein ratio, calculated as described by Holborrow and Johnson, was approximately 1.4:1  for 
both preparations. 
Preparation of F(ab')2 Fragments.--F(ab')2  fragments of anti-SRBC  7S  antibody were 
prepared by Dr. N. R. St. C. Sinclair as previously described (22). 
2gonadherent (N.A.) Spleen Cells.--Nonadherent  spleen cells were prepared using plastic 
tissue culture dishes as previously described (23). This population is deficient in A cells. Ir- 
radiation (1,000 rad) of nonadherent cells inactivates B and T  cells, so that irradiated non- 
adherent spleen cells are deficient in all three classes of immunocompetent cells (A, B, and T 
cells). 
RESULTS 
Effect of 7S Antibody  Treatment on the Immunocompetence of Spleen Cells.- 
The effect of 7S antibody on the immunocompetence of spleen cells was tested 
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of antigen, before culture in Marbrook chambers. The experimental procedure 
is illustrated  in Fig.  1.  Spleen cells were incubated for 1 h  in the presence of 
various concentrations of anti-SRBC 7S antibody (control cells were incubated 
in the absence of antibody). The cells were then washed thoroughly to remove 
free 7S,  and were cultured  in Marbrook chambers in  the presence  of  SRBC. 
After 4 days of incubation, all cultures were assayed for the presence of IgM- 
PFC to SRBC. The pooled results of six experiments are shown in Fig. 2, with 
the results plotted as PFC (percent of control) vs. concentration of 7S antibody 
Spleen cells at 2 x 107/ml 
in medium + 7S antibody 
lh 
370 C 
Spin out cells 
Remove supernatent 
Wash 3x in medium (or PBS) re suspending 
to original volume for each wash 
Re suspend in medium to 2 x 107/ml 
1 
SRBC to 1 x 106/m,~] 
Marbrook culture chambers 
4 days 
PFC 
FIG. 1.  Standard 7S antibody treatment. 
present during treatment of spleen cells.  Treatment with 7S antibody reduced 
the immunocompetence of the spleen cells, and the effect was dose dependent; 
the slope of the curve shown in this figure is --0.47 -4- 0.07. 
It is of interest that the addition  of either  7S antibody or antibody-coated 
SRBC to cultures causes a dose-dependent inhibition with similar kinetics (6). 
The inhibition curve for addition of 7S antibody has a slope of --0.51 -¢- 0.07. 
The inhibition  curve for addition  of SRBC  coated with different amounts of 
antibody has a  slope of --0.51  ±  0.06.  In view of the similar kinetics of inac- 
tivation for all three cases, it is possible that they act through the same mecha- 
nism.  Since  pretreatment  of  cells  with  antibody  is  most  amenable  to  the 
investigation of the mechanism, this procedure was examined more fully. 874  MECIIANISM  OF  7S  INHIBITION 
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]~'IG. 2.  Immunocompetence  of 7S-treated spleen cells. Spleen cells were treated with graded 
concentrations of anti-SRBC 7S antibody, as illustrated in Fig. l, before being cultured (20 X 
l06 cells/culture) with 106 SRBC. The 7S antibody concentration  represents the titer present 
during spleen cell treatment. The points represent the geometric  mean  (GM)  of PFC per 
culture 4- standard errors (SE) expressed as percent of untreated control. The pooled results 
of six experiments are represented  by different symbols. The average control value for the six 
experiments was 950  PFC/culture. The slope of the best-fitted straight line  (least-squares 
method)  is --0.47  4- 0.07 (standard deviation). Cells:  O,  O,  l,  7], •  =  C3B6F1;  G  = 
DBA. 7S antibody: e,  O, i,  [3, A  =  C3B6F1; •  =  C3H. 
Although the most interesting interpretation of the data in Fig. 2 is that the 
antibody directly affects one of the cells in the antigen-sensitive unit, there are 
several  alternative  explanations  for  the  observed  suppression.  They  are  dis- 
cussed below. 
Carry-over  of free 7S antibody:  The simplest explanation for the suppression 
observed in Fig. 2 is that it results from carry-over of free 7S antibody, since it 
is known that addition of 7S antibody to cultures results in an inhibition of the 
response (9,  10, 24). To test for this possibility, the four supernatants obtained 
from the cell washings after 7S  treatment  (see Fig.  1)  were added to cultures 
containing normal spleen cells and antigen. Each supernatant was added, to a 
final concentration of 20%,  to cultures containing 2  X  107 normal spleen cells 
and 1 X  10 ~ SRBC. Since, after the final wash, the cells were always diluted at 
least 20-fold by volume before culturing, the amount of 7S added to the cultures 
in the final supernatant was always greater than  that which would be carried 
over under experimental conditions. The results of these experiments are shown 
in Table I. In all cases, there was no detectable inhibitory effect by the super- 
natant from the final wash. This demonstrates that there is insignificant carry- 
over of free 7S  antibody to the cultures under our standard experimental con- 
ditions. The possibility that antibody is released by treated cells is considered 
in the next section. 
De~'iation of anligen  or release of free  7S  antibody  into  cultures:  Since  sup- 
pression is not the result of transfer of free 7S antibody, it follows that treat- 
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TABLE  I 
Spleen Cell Treatment: Carry-Over of Free 7S Antibody 
Supernatant added* to  cultures (20%) 
PFC (% of control)* 
Exp. 1  Exp. 2  Exp. 3 
--(control)  100  (76-132)§  100  (81-123)1[  100  (82-122)¶ 
1 (from treatment mixture)  < 1  < 1  Not done 
2 (from 1st wash)  13  (9-19)  16  (13-19)  '  Not done 
3 (from 2nd wash)  77  (56-107)  64  (47-86)  Not done 
4 (from 3rd wash)  108  (77-150)  101  (94-107)  108  (103-114) 
* Spleen cells were treated  with anti-SRBC  7S antibody as illustrated  in Fig.  1. Spleen 
cell treatment was carried out at a 7S antibody titer of 2,000 for exps. 1 and 2, and 5,000 
for exp. 3.  (The response of  the  treated  spleen cells  was 8-12%  of controls for these three 
experiments.) After treatment,  the spleen cells were washed as described in Fig.  1, and the 
supernatants were collected. The supernatants were then added,  to a  final concentration 
of 20%, to cultures containing 20 X  106 normal spleen cells and 106 SRBC. Cells, C3B6F1; 
7S antibody, C3B6F1. 
:~ PFC given as percent of control 4- standard error. 
%  =  Geometric mean 4- SE (experimental group) 
X  100. 
Geometric mean of control 
§ Control value (100%), 400 PFC/culture. 
[I Control value, 800 PFC/culture. 
¶ Control value, 1,000 PFC/culture. 
classes of cells in the spleen. This may be the result of an alteration of one of 
the  three cell types  (A,  B,  or T)  involved in the initiation of the response in 
such  a  way  that  the  cell is rendered immunologically incompetent. Alterna- 
tively, the effect may be mediated by a  different class of cells with which the 
7S  antibody has  become  associated.  This latter  effect  could occur  if  (a)  the 
presence of this 7S-associated cell in the cultures would result in destruction of 
the antigen or deviation of  the antigen from the immunocompetent cell com- 
partment (see, for example, reference in footnote 2) or, (b) if 7S antibody could 
be  released  from  this  cell  into  the  culture medium where  it  could  act  by  a 
different mechanism. 
In order  to  test  for  these  possibilities, mixtures of  treated  and  untreated 
spleen cell populations were  cultured.  If  either  of  the  two  mechanisms sug- 
gested  above were  operating,  the  response of  normal cells should be  greatly 
inhibited by the presence of the 7Streated cells in the same culture. If,  on the 
other  hand,  7S  treatment results in one of  the  immunocompetent cell  types 
being rendered incompetent, the untreated cells should respond normally. 
Two types of mixing experiments were done. Since cell density is critical for 
the  culture system,  in all  experiments the  total cell concentration was  kept 
constant at 2  N  10  7 spleen cells/culture. In the first design, the response pro- 
duced by a mixture of 1 X  l0  T 7S-treated cells plus 1 )<  l0  T  untreated cells was 
2 MacDonald, H. R., R. A. Phillips, and R. G. Miller. Antibody-dependent cell-mediated 
cytotoxicity:  evidence favouring non-lymphocytic effector cells. Manuscript  in preparation. 876  MECHANISI~I  OF  7S  INHIBITION 
compared  with  that produced  by 2  )<  107  untreated  cells  (Table  II,  exps.  1 
and  2).  The results  show  that  the response obtained from 1 X  107 untreated 
cells  in  the  presence  of  1  X  107  7S-treated  cells  is  approximately  one-half. 
that produced by 2  X  107 untreated  cells.  In the second design,  the response 
produced by a mixture of  1 X  107 7S-treated cells plus 1 X  107 untreated cells 
was compared with that produced by 1  X  107 untreated  cells  (Table  II, exp. 
3).  For the latter group, the total  cell concentration was made up to 2  X  107 
cells/culture  by the addition of 1 )<  107 irradiated  nonadherent  (N.A.)  spleen 
cells  (see  Materials  and  Methods).  These  cells  were  used  to  adjust  the  cell 
density  since  they do not contain  any functional  cells  of  the  three  types in- 
TABLE II 
Spleen Cell Treatment: Mixing Experiments 
Exp.  Untreated  spleen  7S-treated spleen cells  Irradiated N.A.  PFC (% of control)  cells  spleen cells 
1"  2  X  107  0  0  100  (99-101) 
0  2  X  107  0  14  (12-16) 
1 X  107  1 X  107  0  46  (41-52) 
25  2  X  107  0  0  100  (93-107) 
0  2  X  107  0  23  (20-26) 
1 X  107  1 X  107  0  51  (47-56) 
3§  1 X  107  0  1 X  107  100  (93  107) 
0  1 X  107  1 X  107  26  (23-29) 
1 X  107  1 X  107  0  98  (92-103) 
* All  cultures  contained  106  SRBC.  Control  value,  1,600 PFC/culture.  7S  treatment, 
carried out at titer of 5,000. Cells, C3B6F1; 7S antibody, C3B6F1. 
:~ Control  value,  1,700 PFC/culture.  7S  treatment  carried  out at  titer  of 5,000. Cells 
C3B6F1; 7S antibody, C3B6F1. 
§ Control value, 700 PFC/culture. 7S treatment carried out at titer of 2,000. Cells, C3B6FI; 
7S antibody,  C3B6F1. 
volved in  the  immune  response  (23).  In this  experiment,  1  X  107  untreated 
spleen ceils gave the same response  in the presence or absence of 1 X  107 7S- 
treated cells. 
In both types of mixing experiments,  there is clearly no severe inhibition of 
the untreated cell population by  the 7S-treated  cell population. Therefore, we 
can conclude that the inhibition is not the result of either antigen deviation or 
release  of free  7S  antibody from treated  ceils,  but  the  inhibition  is  probably 
the  result  of an alteration  of one of the  three classes of cells  (A,  B, or T)  in- 
volved in the initiation of the immune response. 
Nonspecific  cytotoxidty  and  specificity:  The  previous  data  suggest  that, 
under  the  conditions  tested,  7S  antibody  acts  by  rendering  specifically  in- 
competent one or more of the cells required for initiation  of antibody produc- S.  ABRAHAMS,  R.  A.  PHILLIPS,  AND  R.  G.  MILLER  877 
tion.  Alternatively,  the  effect could  be  the  result  of  nonspecific  cytotoxicity 
by a component of the 7S preparation.  To test for such cytotoxicity, spleen cells 
were  treated  with  anti-SRBC  7S  or  normal  7S  (isolated  from  the  serum  or 
ascitic fluid  of normal  mice)  as  illustrated  in  Fig.  1.  After being  washed,  the 
cells were cultured  in  the presence  of SRBC  and  their  ability to  respond  was 
compared  with  that of controls.  The results of these experiments  are shown in 
Table III. Treatment  with normal  7S had little, if any,  effect on the ability of 
TABLE  III 
Spleen Cell Treatment: Nonspecific Cytotoxicity 
7S antibody  PFC 
Exp.  Spleen cell treatment 
Source*  Concentration  (% of control) 
1§ 
21[ 
3¶ 
mg/ml  liler* 
-- (Control)  --  --  --  100  (92-109) 
Anti-SRBC 7S  Serum  0.75  3,750  30  (27-33) 
Normal 7S  Serum  0.75  --  98  (87-100) 
--  (Control)  --  --  --  100  (89-112) 
Anti-SRBC 7S  Ascites  0.075  1,500  22  (19-25) 
Normal 7S  Ascites  0.15  --  93  (76-113) 
-- (Control)  --  --  --  100  (87-115) 
Anti-SRBC 7S  Ascites  0.04  800  25  (21-30) 
Normal 7S  Ascites  0.2  --  92  (76-113) 
* 7S  antibody was derived either from serum of C3B6F1 mice or from ascites of C3H 
mice, as described in Materials and  Methods. Anfi-SRBC 7S antibody was prepared  from 
serum  or ascites of mice hyperimmunized  against  SRBC;  normal  7S  was  prepared  in  an 
identical manner  from  serum or ascites  of unimmunized  mice.  Serum-derived anti-SRBC 
7S antibody has a  titer  (anti-SRBC)  of 5,000  at  1 mg/ml;  ascites-derived  anti-SRBC  7S 
antibody has a tiler of 20,000 at 1 mg/ml. 
All titers, here and elsewhere, are hemolytic titers unless otherwise stated. 
§ All cultures contained  20  X  106 spleen cells and  106 SRBC.  Control  value  (100%), 
2,300 PFC/culture. Cells~ C3B6F1. 
l[ Control value, 1,200 PFC/culture. Cells, C3B6F1. 
¶ Control value, 800 PFC/culture. Cells, DBA. 
the  cells  to  mount  an  immune  response  to  SRBC,  while  treatment  with  the 
same concentration, or lower,  of anti-SRBC 7S reduced the immunocompetence 
of  these  cells.  Thus,  the  suppressive  effect  is  not  the  result  of  nonspecific 
cytotoxicity in the isolated component of mouse serum or ascitic fluid. 
The  specificity  of  the  effect  with  regard  to  different  antigens  was  then 
tested. Spleen cells were treated with equal concentrations  of either anti-SRBC 
7S or anti-HRBC  7S, washed,  and cultured in the  presence of one or the other 
of the antigens. The results are shown in  Table IV. Treatment  with anti-SRBC 
7S  reduced  the  ability  of  the  cells  to  respond  to  SRBC  but  not  to  HRBC. 878  MECHANISM  OF  7S  INHIBITION 
TABLE IV 
Spleen Cell Treatment: Specificity 
Exp.  Spleen cell treatment  7S concentration  Antigen  PFC* (% of control) 
1§ 
211 
mg/tnl + 
--  --  SRBC  100  (94  106) 
Anti-SRBC 7S  0.5  SRBC  24  (20  28) 
--  --  HRBC  100  (90-111) 
Anti-SRBC  7S  0.5  HRBC  108  (98-119) 
--  --  SRBC  100  (86-117) 
Anti-HRBC 7S  0.5  SRBC  81  (72  92) 
--  HRBC  100  (76-132) 
Anti-HRBC 7S  0.5  HRBC  19  (13  29) 
* PFC are anti-SRBC PFC when SRBC  is used as antigen, and anti-HRBC PFC when 
HRBC is used as antigen. 
:~ 7S antibody concentrations are expressed as protein concentrations rather than hemo- 
lytic titers, since we found that the hemolytic efficiency of anti-HRBC 7S antibody is not 
the same as anti-SRBC 7S antibody. The 7S antibody is serum derived; the titer of the anti- 
SRBC  7S antibody is 2,500 at 0.5 mg/ml. 
§ Control  values:  2,100 PFC/culture  vs.  SRBC; 200  PFC/culture  vs.  HRBC.  Cells, 
C3B6FI; 7S antibody, C3B6F1. 
1] Control  values:  1,000 PFC/culture  vs.  SRBC;  200  PFC/culture  vs.  HRBC.  Cells, 
C3B6F1;  7S antibody, C3B6FI. 
Similarly,  treatment  of  cells  with  anti-HRBC  7S  altered  their  response  to 
SRBC  only  slightly,  while  severely  inhibiting  the  response  to  HRBC.  The 
effect, therefore, is antigen specific. 
Cellular Site of Action of 7S Antibody-Mediated Inhibition.--Since treatment 
of spleen cells with specific 7S antibody results in a functional depletion of one 
of the immunocompetent cells, identification of the depleted cell type provides 
a  method  for  elucidating the  cellular site of  action of  7S  inhibition.  Results 
from other groups (5,  25)  have demonstrated  that 7S antibody-treated spleen 
cells  respond  normally  to  erythrocyte  antigens  when  assayed  in  irradiated 
recipients. However,  the in vivo assay system  requires  only functional B  and 
T  cells,  since  radiation-resistant A  cells are  supplied  by  the  recipients  (23). 
The in vitro system, on the other hand, requires immunocompetent cells of all 
three  types. This indirect reasoning infers that  the cell being affected by our 
treatment is the radiation-resistant A  cell. 
In order to test this hypothesis, three different assay systems were used: 
(a)  The  standard  in vitro  system,  which  requires  competent  A,  B,  and  T 
cells. 
(b)  The  standard  in  vivo  system,  in  which  spleen  cells and  SRBC  are in- 
jected into  recipients 2  h  after irradiation and  spleens  are  assayed for  IgM- 
PFC 7 days later. This system requires immunocompetent B  and T  cells in the 
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(c)  The in vivo system of Gorczynski et al. (23) in which mice are irradiated 
72 h  before injection of spleen cells and SRBC. These recipients are deficient in 
A  cells as well as B  and T  cells, and thus provide an in vivo assay system in 
which immunocompetent cells of all three types are required. 
The  immunocompetence  of control  and  anti-SRBC  7S-treated  spleen  cells 
(treatment as in Fig. 1) was tested in all three systems. The results are shown 
in Table V. A  reduction in the immunocompetence of spleen cells as a result of 
TABLE V 
Immunocompetence of 7S-Treated Spleen Cells Detected  By Means of Different Assay Systems* 
Exp.  Spleen cell treatment 
PFC~c (% of control) 
2 h-irradiated  72 h-irradiated 
In vitro  recipients§  recipients§ 
--(Control)  100  (87-115)  100  (90-111)  100  (81-123) 
7SI[  15  (11-19)  101  (88-117)  25  (20-32) 
2  --(Control)  Not done  100  (78-128)  100  (87-115) 
7SI1  Not done  65  (45-94)  11  (7-17) 
3  -- (Control)  100  (74-136)  100  (86-116)  Not done 
7SI]  24  (20-28)  160  (131-195)  Not done 
Average % of control for  20  108  18 
7S-treated cells 
* For the in vitro assay, 15  X  10 6 spleen cells were cultured with 1 X  10 6 SRBC.  PFC 
were assayed on day 4. For the in vivo assays, 15 X  10 6 spleen cells were injected with 1 X 
10  8 SRBC. PFC were assayed on day 7. 
Control values: 
Exp. 1  Exp. 2  Exp. 3 
In vitro (PFC/culture)  700  Not done  400 
2 h recipients (PFC/spleen)  500  600  400 
72 h recipients (PFC/spleen)  900  600  Not done 
§ Recipients are C3B6F1. 
][ 7S treatment of spleen cells as illustrated in Fig. 1. Treatment was carried out with anti- 
SRBC  7S antibody at a titer of 3,000. (7S antibody, C3H; cells, C3B6F1). 
7S  treatment  was  observed in  the in vitro system and  in  the  72  h-irradiated 
recipients, but not in  the 2  h-irradiated recipients. It is clear that  the defect 
caused  by 7S  treatment  is detected only in  systems which  require functional 
A  cells. 
Reconstitulion.--The  results  described  above  suggest  that  7S  treatment  of 
spleen cells results in  a  functional depletion of A  cells. If  this is  the  case,  it 
should be possible to reconstitute a  7S-treated spleen cell population by addi- 
tion of A  cells. It has been  shown  that peritoneal exudate cells provide a  rich 
source of A  cells (26). 880  MECHANISM  OF  7S  INHIBITION 
The  reconstituting ability of A  cells was  tested by culturing  15  X  106  7S- 
treated and control spleen cells in the presence or absence of 5  X  105 peritoneal 
cells. The results are shown in Table VI. Treatment of spleen cells with 7S anti- 
body  resulted  in  93 %  inhibition of  the  response  (groups  1  and  2).  Group  3 
demonstrates that the 7S-treated spleen  cells can be  completely reconstituted 
by the addition of peritoneal cells. 
The increase in the response provided by the peritoneal cells may be due to 
the  replenishment  of  the  cell type which  has  been  altered by  7S  treatment; 
alternatively, the effect may be the result of an  unrelated synergism between 
the  spleen  cells and  peritoneal cells. Two  pieces of  evidence make  the  latter 
interpretation unlikely. First, there is clearly no synergism between peritoneal 
cells and  untreated spleen cells (Table VI,  group 4).  Secondly, the peritoneal 
TABLE  VI 
Spleen Cell  Treatment: Reconstitution with Peritoneal Cells 
Spleen cells  Peritoneal cells 
Group  PFC (% of control) 
Treatment  Cells/culture  Treatment  Cells/culture 
1  --  15  X  106  --  0  100  (82-122)* 
2  7S~:  15  X  106  --  0  7  (6-8) 
3  7S  15  X  106  --  5  X  10.5  120  (110-130) 
4  --  15  X  106  --  5  X  10 ~  90  (83-97) 
5  7S  15  X  10 ~  7S§  5  )  l0  s  33  (27-40) 
6  --  15  X  106  7S  5  X  10 .5  101  (87-119) 
* All cultures contained 106 SRBC. Control value, 550 PFC/culture. 
Spleen cells (C3B6F1) were treated with anti-SRBC 7S antibody in the standard way 
(see Fig. 1) at a titer of 5,000. (7S antibody, C3B6F1.) 
§ 7S treatment of peritoneal cells was carried out in exactly the same manner as 7S treat- 
ment of spleen cells. 
cells are themselves sensitive to 7S treatment: their ability to reconstitute was 
severely reduced by 7S  antibody treatment  (group 5).  Since the  treated peri- 
toneal cells did not inhibit the response provided by normal spleen cells (group 
6),  the  treated cells could not have  transferred significant amounts of free 7S 
antibody. These data indicate that reconstitution is the result of the addition 
to the spleen cells of a particular class of cells and that this class of cells can be 
functionally depleted by 7S  treatment. 
Characlerization of the Reconstituting CelL--The results presented above sug- 
gest that the cell type which provides reconstitution is the same as that which 
is altered by 7S antibody treatment of spleen cells. This then provides an inde- 
pendent method of characterizing the affected class of cells. 
Of the three cell classes involved in the initiation of an immune response to 
heterologous erythrocytes,  two  are radiation  sensitive  (B  and  T)  and  one  is 
radiation resistant (A). In order to characterize the reconstituting cell in this S.  ABRAHAMS,  R.  A.  PHILLIPS,  AND  R.  G.  MILLER  881 
regard,  peritoneal  cells were irradiated  (1,000  tad)  before being  added  to  7S- 
treated  spleen  cells.  The  results,  shown  in  Table  VII,  demonstrate  that  the 
ability to reconstitute  is radiation  resistant,  indicating  that the reconstituting 
cell, and thus by inference the cell in the splenic population which is altered by 
7S  treatment,  is  the  radiation-resistant  accessory cell.  The  remaining  groups 
in this  table  are further controls demonstrating  that 5  >(  105 peritoneal  ceils, 
whether  irradiated  or not,  do  not  themselves  produce  any PFC  in  cultures 
made up to optimal cell density with irradiated spleen cells. 
The quantification of the ability of irradiated peritoneal cells to reconstitute 
7S-treated  spleen  is  shown  in  Fig.  3.  Different  concentrations  of  irradiated 
peritoneal  cells were added to control and 7S-treated spleen cells, and the mix- 
tures  were  cultured  as usual.  While  the peritoneal  cells  did  not  significantly 
TABLE VII 
Radiation Sensitivity of Reconstituting Cell 
Spleen cells  Peritoneal cells  PFC (% of control) 
Treatment  Cells/culture  Treatment  Cells/culture  Exp. 1"  Exp. 2, 
--  15  X  106  --  0  100  (88-114)  100  (85-118) 
7S§  15  >(  106  --  0  22  (17-28)  3  (1-4) 
7S  15  )<  106  1,000  tad  5  X  105  80  (73-88)  124  (109-140) 
--  15  )<  106  1,000  rad  5  X  105  78  (75-82)  102  (96-107) 
1,000  rad  15  X  106  --  0  Not done  <0.1 
1,000  rad  15  >(  106  --  5  X  105  Not done  <0.i 
1,000  rad  15  X  106  1,000  rad  5  X  105  Not done  <0.1 
* All cultures contained  106 SRBC. Control value,  1,000 PFC/culture.  (Cells, C3B6F1.) 
:~ Control value, 2,300 PFC/culture. (Cells, C3B6F1.) 
§ Spleen cells treated with anti-SRBC  7S antibody at a fiter of 5,000. (7S antibody: exp. 
1, C3B6F1; exp. 2, C3H.) 
enhance the untreated spleen cell response at any of the given concentrations, 
significant reconstitution  of the  7S-treated  spleen cells was obtained at a  con- 
centration of 5 X  105 peritoneal cells. 
There  is  evidence  that  some  T  cell  functions  are  radiation  resistant  (see 
reference  27 for discussion).  To demonstrate  that reconstitution  of 7S-treated 
spleen cells is not the result of a  radiation-resistant  T  cell function,  the sensi- 
tivity of the reconstituting cell to anti-O antibody was tested.  In these experi- 
ments, peritoneal cells were treated with anti-0 antibody as described in Mate- 
rials  and  Methods before being  added  to 7S-treated  spleen  cells.  The results, 
along with  the appropriate  controls, are shown in Table VIII. It is clear that 
the  reconstituting  ability  of  peritoneal  cells  is  resistant  to  treatment  with 
anti-O antibody. 
Sedimentation Analysis of the Reconstituting  CelL--The three immunocompe- 
tent cell classes present in the spleen have been characterized with respect  to 882  MECHANISM  OF  7S  INHIBITION 
I00 
,0  qa 
? 
o  6 25  12.5  25  50 
Irradiated  peritoneol  cells  per culture (xIO  -4) 
FI6. 3. Quantification  of reconstituting  ability  of irradiated  peritoneal  cells. 15  )Z  106 
untreated  (e) or 7S-treated  (O) spleen cells were cultured with graded doses of irradiated 
(1,000 R) peritoneal cells (and SRBC). Points are GM =k SE as percent of control. The con- 
trol  value (untreated  spleen cells alone) was 850 PFC/culture. Ceils, C3B6F1; 7S antibody, 
C3H. (7S treatment  of ceils was carried out at a titer  of 3000.) 
their sedimentation velocities (23, 28-30) with B and T  cells having sedimenta- 
tion velocities  of 3  4  mm/h,  and  A  cells,  4-6  mm %.  It would,  therefore,  be 
useful  to  characterize  the  reconstituting  cell  with  respect  to  this  parameter, 
particularly from a spleen-derived source of cells. Irradiated spleen cells should 
provide a spleen-derived source of reconstituting cells. However, we found that 
the  concentration  of irradiated  spleen  cells  required  for full  reconstitution  is 
approximately the same as the concentration of 7S-treated cells cultured. Since 
cell density is critical  in the  culture  system,  this  makes reconstitution  experi- 
ments with  irradiated spleen  cells  cumbersome  and  difficult  to  quantify.  This 
problem was overcome using the method of Gorczynski et al. (23), who demon- 
strated that the A cell content of spleen is greatly increased by culturing spleen 
cells for 3 days (in Marbrook chambers) in the absence of antigen. 
The ability of spleen cells to reconstitute  after 3  days of culture followed by 
irradiation  (1,000  rad)  is  shown  in  Table  IX.  These cells provide significant 
reconstitution and the reconstituting ability is sensitive to 7S treatment.  These 
cells were,  therefore, used as a  spleen-derived source of cells for sedimentation 
analysis of the reconstituting cell population. 
Sedimentation was carried out as described in Materials and Methods.  After 
sedimentation,  fractions were combined into four pools, irradiated  (1,000  rad), S.  ABRAHAMS,  R.  A.  PHILLIPS,  AND  R.  G.  MILLER  883 
TABLE VIII 
A nti-O Sensitivity of Reconstituting  Cell 
Spleen ceils  Peritoneal ceils  ]  PFC (~ cf control) 
Treatment  Cells/culture  Treatment  Cells/culture,  Exp. 1"  Exp. 2:~ 
I 
7S§ 
7S 
7S 
Anti-0¶ 
C' 
Anti-O+ C' 
15  X  106 
15  X  106 
15  X  106 
15  X  10  {; 
15  X  I0  '~ 
15  X  10 6 
15  X  106 
15  X  10 6 
15  X  10 6 
F 
c'Ji 
Anti-6 +  C' 
C' 
Anti-9 -}- C' 
0 
0 
5  X  10  '~ 
5  X  10 '~ 
5  X  10 '~ 
5  X  10  '~ 
0 
0 
0 
100  (90  111) 
.5  (4-6) 
72  (63  82) 
79  (66-94) 
Not done 
Not done 
85  (74 98) 
96  (81  113) 
2  (1  3) 
100  (87  115) 
24  (21  28) 
74  (69  81) 
73  (62-86) 
125  (120 130) 
109  (97  122) 
Not done 
Not done 
30  (19-47) 
* All cultures  contained  106 SRBC. Control value, 400 PFC/culture. (Ceils, C3B6F1.) 
Control value, 500 PFC/culture. (Cells, C3B6F1.) 
§ 7S treatment of spleen cells was carried out, in the usual manner, with anti-SRBC  7S 
antibody at a titer of 1,000. (7S antibody, C3B6F1.) 
H  Peritoneal cells were treated  with C' alone (as control) or anti-0 antibody followed by 
C' as described in Materials and Methods. 
¶ In order to test the effectiveness of the anti~ treatment, spleen cells were treated with 
anti-0 antibody alone, GPS  (C')  alone, or anti-0 antibody followed by C' as described in 
Materials and Methods. 
and added back to 7S-treated spleen ceils to a final concentration of  15  X  10 6 
7S-treated spleen cells plus 1.5  X  10 6 irradiated, fractionated cells/culture. The 
results are shown in Fig. 4. The base line is provided by 15  X  10  6 7S-treated 
cells alone, and the control by 15  X  10  6 untreated spleen cells. As can be seen, 
substantial reconstitution was  provided  only by  cells  with  a  sedimentation 
velocity of  >5  mm/h.  This observation provides  two  pieces  of information. 
First, the reconstituting cell is a distinct class of cells, separate from the  major 
cell peak; therefore, reconstitution is unlikely to be the result of a  nonspecific 
"feeder" effect. Secondly, the sedimentation velocity of the reconstituting cell 
is similar to that of A cells (4-6 mm/h) and not to B and T  lymphocvtes, which 
have sedimentation velocities in the range of ,3  4 mm/h. 
To verify that the sedimentation velocity of the reconstituting cell in normal 
spleen is the same as that in 3 day-cultured spleen, sedimentation analysis of 
the reconstituting cell in normal spleen was carried out. After sedimentation of 
normal spleen ceils, fractions were combined into three pools, irradiated, and 
added back to 7S-treated spleen cells to a  final concentration of 15  X  10 6 7S- 
treated  spleen  cells  plus  3.5  5  X  10 6 irradiated,  fractionated  cells/culture. 
The results are presented in Table X. While the degree of reconstitution is not 
as great as that obtained with cultured spleen cel!s, it is clear that significant 
reconstitution is provided by cells with  sedimentation velocities greater  than 884  MECHANISM  OF  7S  INHIBITION 
TABLE IX 
Reconstitution with Irradiated 3 Day-Cultured Spleen Cells 
Spleen cells  Irradiated 3 day-cultured  spleen cells+  +  PFC (% of control) 
Treatment*  Cells/culture  Treatment  Cells/culture  Exp. 1  Exp. 2 
--  15  X  106  --  0  100  (83-12t)§  100  (90-111)[I 
7S  15  ×  106  --  0  19  (17-22)  24  (20-29) 
7S  15  X  106  --  7.5  X  106  78  (66-91)  88  (78-99) 
--  15  X  10  6  --  7.5  X  106  123  (119-128)  99  (69-141) 
Exp. 3 
--  15  X  106  --  0  100  (84-119)¶ 
7S  15  X  10  s  --  0  8  (5-11) 
7S  15  X  106  --  5  X  106  48  (35-66) 
--  15  X  106  --  5  X  10  s  66  (54-81) 
7S  15  X  10  6  7S  5  X  10  6  8  (5-11) 
--  15  X  106  7S  5 X  106  52  (40-67) 
* 7S treatment of spleen cells as usual. Titers for treatment: exp. 1, 2,500; exp. 2,  1,250; 
exp. 3, 1,000. 7S antibody, C3B6F1. 
:~ Spleen cells were cultured  in Marbrook chambers for 3 days in the absence of antigen. 
The cells were then irradiated  (1,000  rad) and combined with untreated or 7S-treated spleen 
cells as shown in the table. For exp. 3, a portion of the spleen cells was treated with 7S anti- 
body before being cultured  for 3 days. These cells provided 7S-treated, irradiated,  3 day- 
cultured cells. 
§ All cultures contained  106 SRBC. Control value, 1,500 PFC/culture. (Cells, C3B6F1.) 
]I Control value, 1,800 PFC/culture. (Cells, DBA). 
¶ Control value, 1,200 PFC/culture. (Cells, DBA). 
4.5  mm/h.  This  result  supports  our  interpretation  that  reconstitution  is 
effected by A  cells. 
Mechanism  of the Effect.--The  results presented above indicate that  treat- 
ment of  spleen cells with  7S  antibody results in an  alteration of  the  A  cell 
population. This could be the result of either an intrinsic alteration of the A 
cells by exposure to  7S  antibody, or,  alternatively, the formation of  a  stable 
association between 7S  antibody and  these  cells.  Since  the  effect  is  antigen 
specific,  while  A  cells  are  apparently not  antigen restricted  (23),  the  latter 
mechanism is inferred. 
In order to test whether 7S antibody becomes cell associated during incuba- 
tion, FITC-7S conjugates were formed as described in Materials and Methods. 
FITC-labeled mouse albumin was used as the control. Spleen cells were  then 
treated in the standard way with the labeled preparations. The labeled 7S was 
used at a concentration of 0.14 mg/ml (ascites derived, titer at 0.14 mg/ml = 
2,000),  the  labeled albumin, at  a  concentration of  0.06  mg/ml. Assuming a 
molecular weight of 160,000 for 7S antibody and 70,000 for albumin, this means 
that approximately the same number of labeled molecules were present in both S. ABRAHAMS,  R. A. PHILLIPS, AND R. G. MILLER  885 
'2 
6 
3 
~-  2 
I00 
90 
"~ 70 
5o 
4o 
30 
20 
,o 
'% 
/\ 
o"  \ 
d" 
k°o~-o  o oo  o  ° 
Untreated spleen + 
( control ) 
7S-treated  spleen  l 
plus fractions 
I  2  3  4  6 
Sedimentation  velocity (ram/h) 
7S-treated 
spleen alone 
Fla. 4.  Sedimentation analysis of reconstituting cells. 3 day-cultured spleen cells (see text) 
were separated by velocity sedimentation.  Fractions were combined to form four pools (con- 
taining ce]ls with sedimentation velocities  of 2-3  mm/h,  3-4 mm/h, 4-5 mm/h,  and 5-6 
mm/h)  and each pool of cells was then irradiated (1,000 rad). Upper graph: sedimentation 
profile of 3 day-cultured spleen cells.  O----, total cells;  C)---O, nucleated cells. Lower 
graph: response obtained from  15  X  106 7S-treated spleen cells cultured alone, or combined 
with 1.5 X  106 irradiated fractionated cells from each of the pools described above. Response 
represented as GM 4- SE as percent of control. Control value, provided by 15 X  106 untreated 
spleen cells, was 850 PFC/culture. Cells, DBA; 7S antibody, C3B6F1. (7S treatment of spleen 
cells was carried out at a titer of 1,500.) 
incubation mixtures. After treatment and washing, the spleen cells were scored 
for percent fluorescing cells, and the results are shown in Table XI. In the 7S- 
treated group, 1% of total cells (~2 % of nucleated cells) became labeled, while 
in the albumin-treated group just 0.03 % of total cells (0.07 % of nucleated cells) 
became labeled. Thus, treatment with 7S resulted in a specific association of 7S 
with a  small proportion of cells. 
It is not clear from the data presented whether 7S becomes associated with a 
small proportion of cells of all classes, or specifically with a larger proportion of 
a  distinct class of cells. To clarify this point, cells were incubated with FITC- 
conjugated 7S as described above and then subjected to sedimentation analysis. 
After  sedimentation,  each  fraction  was  scored  for  cell  number  and  percent 
fluorescing cells. The  results are shown  in  Fig. 5,  with both  total fluorescent 
cells per  fraction  and  percent fluorescent cells per fraction  being plotted vs. 886  MECHANISM  OF  7S  INHIBITION 
TABLE  X 
Reconstitution with Irradiated Spleen Cell Fractions 
Spleen cells  Irradiated spleen cell fractions* 
Treatment  Cells/culture  Sedimentation  velocity  Cells/culture 
PFC (% of control) 
mm/h 
--  15  X  10 ~  --  0  100  (96-105){ 
7S§  15  X  106  --  0  25  (21-29) 
7S  15  X  10 6  2.5-3.5  5  X  106  25  (19  33) 
7S  15  X  10 6  3.5  4.5  5  X  10  ~  21  (19-24) 
7S  15  M  106  4.5  6.0  3.5  X  106  48  (39-59) 
* Normal spleen cells were separated by velocity sedimentation as described in Materials 
and Methods. Fractions were combined to form three pools (containing cells with sedimenta. 
tion velocities of 2.5-3.5  ram/h, 3.5-4.5  mm/b, and 4.5-6.0  ram/h)  and each pool was ir- 
radiated  (1,000  rad).  Irradiated  cells from  each pool were  then combined with  7S-treated 
spleen cells as shown in the table. 
:~ All cultures contained  106 SRBC.  Control value,  950  PFC/culture.  (Cells,  C3B6F1.) 
§ Spleen cells treated  with anti-SRBC  7S  antibody in  the usual  manner,  at  a  tiler  of 
1,500.  (7S antibody, C3B6F1.) 
TABLE  XI 
Association ~;j" FITC-Confitgated 7S Antibody iciil/t Spleen Cells 
Spleen cell treatment  Total cells counted  Fluorescent*  cells  % fluorescent cells 
FITC-7S:~  2,500  25  1.0 
FITC-albumin§  8,500  3  0. 035 
* Fluorescent cells were scored using a  Zeiss Universal microscope with fluorescence at- 
tachment (Carl Zciss, Inc., New York). 
~: Spleen cells were treated, in the usual manner, with FITC-labeled anti-SRBC 7S anti- 
body at a concentration of 0.14 mg/ml. (7S antibody, C3B6F1; cells, DBA). 
§ Spleen cells were treated with FITC-labeled mouse albumin at a  concentration of 0.06 
mg/mL This concentration is equivalent, on a molar basis, to 7S antibody at a concentration 
of 0.14 mg/ml. Both the  FITC-7S  and  FITC-albumin  preparations  have  a  fluorescein  to 
protein ratio of 1.4:1  (see Materials and Methods). 
sedimentation  velocity.  The  maximum  enrichment  is  obtained  at  6  mm/h; 
the distribution of total number  of fluorescent cells is very similar to the A  cell 
profile  found  by  Gorczynski  et  al.  (23).  This  finding  demonstrates  that  7S 
antibody  becomes  associated  with  a  distinct  class  of  cells  and  is  compatible 
with this class being the A  cell population. 
Inhibitory Eject of Intact 7S Antibody and F(ab02 Fragments.--If  the ability 
of  7S  antibody  to  alter the A  cell population is indeed the result of its associa- 
tion  with  this  cell,  it  might  be  expected  that  intact  7S  molecules,  but  not 
F(ab'),~ fragments, will alter the abilit  5  of a  spleen cell population to mount  an 
inmmne response, since it is known that the cytophilic property of 7S antibody 
resides in the Fc portion of the molecule (31). S.  ABRAHAMS~ R.  A.  PHILLIPS~  AND  R.  G.  MILLER  887 
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FIG. 5.  Sedimentation analysis of cells which become associated with 7S antibody. Spleen 
cells were treated with FITC-conjugated 7S antibody and then separated by velocity sedi- 
mentation. Upper graph:  •  0,  total cells per fraction; O---C), nucleated cells per frac- 
tion. Lower graph:  •--@,  total fluorescent cells per fraction; N  X, percent fluorescent 
ceils per  fraction.  Percent fluorescent cells of  unfractionated  spleen  (nucleated)  =  1.5~o. 
Cells, DBA; 7S antibody, C3B6FI.  (Treatment of spleen cells with FITC-TS antibody was 
carried out at a  concentration of 0.14 mg/ml; titer of FITC-TS at 0.14 mg/ml is 2,000.) 
F(ab')2 fragments were very kindly prepared by Dr. N. R. St. C. Sinclair as 
previously described  (22).  Spleen cells were treated as usual  with equivalent 
concentrations of intact anti-SRBC 7S antibody or F(ab')~ fragments prepared 
from the same sample of 7S. Equivalence was based on hemagglutination titers, 
since the hemagglutinating efficiency of F(ab')2 is comparable to that for the 
intact  molecule  (22).  The results  are  shown  in  Table XII.  Treatment with 
intact 7S antibody, but not with the F(ab')2 fragments, reduces the immuno- 
competence of the spleen cells. This difference in properties of the two molecules 
indicates that the effect of 7S antibody on the immunocompetence of A cells is 
a result of the association of 7S antibody with this cell, and that the association 
is mediated by an Fc-binding site on the A cell. 
DISCUSSION 
We have shown that exposure of spleen cells to specific 7S antibody, in the 
absence of antigen, results in a functional depletion of A  cells with respect to 888  MECHANISM  OF  7S  INHInITION 
TABLE  XII 
Spleen  Cell Treatment:  Comparison  of Intact 7S Molecules  and F(ab') : Fragments 
Spleen cell treatment  PFC (% of control) 
Hemagglutination  Exp. 1"  Exp. 2~  Treatment  titer 
--  --  100  (95-105)  100  (97-103) 
7S§  125  28  (24-33)  34  (32-37) 
7S11  125  29  (26-32)  Not done 
F(ab%¶  125  109  (95-125)  97  (90-104) 
* All cultures contained 15 X  10 ~ spleen cells and 106 SRBC. Control value, 1,500 PFC/ 
culture. (Cells, DBA.) 
:~ Control value, 2,000 PFC/culture.  (Ceils, DBA.) 
§ Untreated  anti-SRBC antibody  (C3H). A hemagglutinafion titer  of 125 is equivalent 
to a facilitated hemolytic titer of 2,000. 
II Same sample of 7S antibody, incubated with inactive pepsin (control for F[ab']2 prepa- 
ration). 
¶ Same sample of 7S antibody, digested with pepsin (see Materials and Methods). 
the antigen against which the antibody carries its specificity. This effect appears 
to be the result of an association between A cells and 7S antibody, mediated by 
an Fc receptor site. 
A necessary early step in the induction of an immune response to an intact 
erythrocyte antigen  is  the interaction  of A  cells  (macrophages)  and  antigen, 
presumably resulting  in  the presentation  of  the  antigen,  in  an  immunogenic 
form, to the lymphoid compartment (32-34). Our results suggest that previous 
association of specific 7S  antibody with A  cells alters  the  subsequent A  cell- 
antigen interaction in such a way that antigen is not presented to the lymphoid 
compartment in an immunogenic form. Presumably, previous association of 7S 
antibody with antigen would similarly alter the subsequent A cell-antigen inter- 
action,  and our experiments with  antigen-antibody complexes are compatible 
with this prediction (6). 
The importance of this mechanism with respect to normal feedback control 
of an in vivo immune response is at present a matter of speculation. It has been 
shown that SRBC-bearing macrophages from normal but not from 7S antibody- 
treated donors induce a response in normal recipients (5, 35, 36), which implies 
that 7S antibody can alter the interaction of A cells and erythrocytes in vivo as 
well as in vitro. Furthermore, it has been shown that inhibition of the immune 
response  to  SRBC  in  vivo is  accomplished far more efficiently by intact  7S 
antibody than by F(ab')2 fragments (37).  This observation is compatible with 
the proposed mechanism playing a significant role in vivo. 
During the course of a normal immune response, antigen, 7S antibody, and A 
cells would all be present. Under these conditions, the 7S antibody could either 
become associated with A cells (via the Fc portion of the molecule) or, alterna- 
tively, form complexes with the antigen (via the Fab portion). In either case, the S.  ABRAHAMS,  R.  A.  PHILLIPS, AND  R.  G.  MILLER  889 
subsequent interaction of A  cells and antigen, which normally results in  the 
presentation of immunogenic antigen to the lymphoid compartment, would be 
altered by the presence of 7S antibody. This model is compatible with the feed- 
back model of Bystryn et al.  (38),  and identifies the imnmnogen-containing 
compartment as the A cell. 
While we have demonstrated that specific antierythrocyte 7S antibody can 
inhibit the response to erythrocytes by altering the interaction of A cells and 
erythrocytes, this certainly does not rule out the possibility that other mecha- 
nisms  may operate  under  different conditions.  Diener  and  Feldmann  (11) 
have clearly demonstrated that two separate mechanisms, both different from 
that  postulated  above,  are  involved in  antibody-mediated inhibition  of  an 
A cell-independent antigen. These two mechanisms are (a)  antigen neutraliza- 
tion by saturation of antigenic determinants, and (b) inactivation of B cells as a 
result of an interaction of antigen and antibody with B cell receptors. Sinclair 
and  Chan  (12) have postulated  that  7S  antibody can  act  by  "turning off" 
lymphoid cells after a response has been induced. MacDonald et al.  2 have shown 
that, in the presence of anti-SRBC 7S antibody, destruction of SRBC, mediated 
by  polymorphonuclear  leukocytes,  can  occur.  Thus,  7S  antibody-mediated 
immunoregulation may represent  a  complex homeostatic control  system in- 
volving several distinct mechanisms. 
SUMMARY 
A cell culture system was used to investigate the mechanism of action of the 
feedback inhibition caused by specific 7S antibody. It was found that preincu- 
bation of spleen cells with specific 7S antibody led to a marked reduction in the 
in vitro response of the treated spleen cells to the antigen used to prepare the 
antibody. The inhibition was not caused by a carry-over of free antibody nor 
by the release of 7S antibody from the cells. Rather, the preincubation appeared 
to specifically inactivate one of the cells required for initiation of an in vitro 
response. Since the suppression could be reversed by addition of untreated cells, 
it was possible to characterize the properties of the reconstituting cell. This cell 
is identified as the nonlymphoid accessory cell  (A cell) by several criteria.  (a) 
Suppression can be demonstrated only in assay systems requiring functional 
A cells. (b) The most active sources for reconstitution are also good sources for 
A cells. (c) The sedimentation velocity of the reconstituting cell is identical with 
that for A  cells.  (d)  Like A  cells,  the reconstituting cell  is resistant to high 
doses of ionizing radiation.  (e)  The reconstituting ability is not affected by 
anti-0 antibody. Of the three cells  required for the initiation of an immune 
response,  A  cells,  bone marrow-derived cells,  and  thymus-derived cells,  the 
data are only compatible with the reconstituting cell being an A cell. 
Additional experiments suggest that the Fc portion of 7S antibody binds to 
the  surface of A  cells.  Thus,  fluorescein isothiocyanate-labeled 7S  antibody 
binds specifically to cells with properties similar to those described above, and 890  MECHANISM O~F  7S  INHIBITION 
F(ab')2 fragments, lacking Fc portion, are unable to cause immunosuppression 
when they are preincubated with spleen cells. It is possible that this binding is 
related to the specific suppression caused by 7S antibody molecules. 
We thank  Dr. N. R. St. C. Sinclair for preparing F(ab') 2 fragments for us. The technical 
assistance of Mrs. J. Madrus and Mr. R. Kuba is gratefully acknowledged. 
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